Advertisement

Current Geriatrics Reports

, Volume 7, Issue 3, pp 181–189 | Cite as

Tailoring Treatment in Obstructive Lung Disease: Asthma, COPD, Asthma/COPD Overlap and Eosinophilic COPD

  • Joseph Walsh
  • Andrew Scott
  • Robert Rutherford
Pulmonology and Respiratory Care (D Breen, Section Editor)
  • 14 Downloads
Part of the following topical collections:
  1. Topical Collection on Pulmonology and Respiratory Care

Abstract

Obstructive lung disease exacts a huge global health burden with a high prevalence of both asthma and COPD in elderly patients.

Purpose of Review

This review is to update the general and elderly care physician on diagnosis and management of COPD and asthma and the recently established disease asthma/COPD overlap (ACO) and the particular challenges treating obstructive lung disease in elderly patients.

Recent Findings

COPD pharmacology has changed considerably in the last decade with a dramatic increase in the utility of single and dual long-acting bronchodilators both for symptom and exacerbation attenuation. The emergence of ACO and the COPD phenotype eosinophilic COPD also appear to require nuanced therapeutic approaches. There is also a strong emphasis now on screening and treating comorbid conditions in COPD. In asthma the emergence of tailored therapy for different severe asthma phenotypes is also discussed.

Summary

Obstructive lung diseases are very common in elderly patients and both diagnosis and treatment of these conditions is more challenging than in younger patients.

Keywords

Asthma COPD Exacerbation Asthma/COPD overlap Eosinophilic COPD 

Notes

Compliance with Ethical Standards

Conflict of Interest

Robert Rutherford, Andrew Scott and Joseph Walsh declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Asthma GIf. Global Strategy for asthma management and prevention, 2018. 2018.Google Scholar
  2. 2.
    Burgess JA, Matheson MC, Gurrin LC, Byrnes GB, Adams KS, Wharton CL, et al. Factors influencing asthma remission: a longitudinal study from childhood to middle age. Thorax. 2011;66(6):508–13.  https://doi.org/10.1136/thx.2010.146845.CrossRefPubMedGoogle Scholar
  3. 3.
    Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.  https://doi.org/10.7189/jogh.05-020415.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32.  https://doi.org/10.1183/09031936.06.00124605.CrossRefPubMedGoogle Scholar
  5. 5.
    Disease GIfCOL. Global STRATEGY for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report). 2018.Google Scholar
  6. 6.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42.  https://doi.org/10.1016/s2213-2600(15)00106-x.CrossRefPubMedGoogle Scholar
  7. 7.
    Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2013;187(9):1016–27.  https://doi.org/10.1164/rccm.201303-0437ST.CrossRefPubMedGoogle Scholar
  8. 8.
    Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161(1):309–29.  https://doi.org/10.1164/ajrccm.161.1.ats11-99.CrossRefPubMedGoogle Scholar
  9. 9.
    Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, et al. Indirect airway challenges. Eur Respir J. 2003;21(6):1050–68.CrossRefPubMedGoogle Scholar
  10. 10.
    Dykewicz MS. Occupational asthma: current concepts in pathogenesis, diagnosis, and management. J Allergy Clin Immunol. 2009;123(3):519–28.  https://doi.org/10.1016/j.jaci.2009.01.061. quiz 29-30CrossRefPubMedGoogle Scholar
  11. 11.
    Network BTSSIG. SIGN 153 British guideline on the management of asthma. 2016.Google Scholar
  12. 12.
    Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;(1):Cd003559.  https://doi.org/10.1002/14651858.CD003559.pub4
  13. 13.
    Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–16.  https://doi.org/10.1111/j.1398-9995.2004.00772.x.CrossRefPubMedGoogle Scholar
  14. 14.
    NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 278. Omalizumab for treating severe persistent allergic asthma. 2013.Google Scholar
  15. 15.
    • Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207.  https://doi.org/10.1056/NEJMoa1403290. This was a tremendous breakthrough in severe asthma care as previously only atopic subjects could benefit from targeted therapy. CrossRefPubMedGoogle Scholar
  16. 16.
    Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97.  https://doi.org/10.1056/NEJMoa1403291.CrossRefPubMedGoogle Scholar
  17. 17.
    Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66.  https://doi.org/10.1016/s2213-2600(15)00042-9.CrossRefPubMedGoogle Scholar
  18. 18.
    Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90.  https://doi.org/10.1016/s2213-2600(14)70201-2.CrossRefPubMedGoogle Scholar
  19. 19.
    NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 479. Reslizumab for treating severe eosinophilic asthma. 2017.Google Scholar
  20. 20.
    NICE. National Institute for Health and Care Excellence L. Technology appraisal guidance TA 431. Mepolizumab for treating severe refractory eosinophilic asthma. 2017.Google Scholar
  21. 21.
    Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573–81.  https://doi.org/10.2147/copd.s16975.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009;64(10):894–900.  https://doi.org/10.1136/thx.2008.110619.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626–33.  https://doi.org/10.1378/chest.10-2948.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lokke A, Ulrik CS, Dahl R, Plauborg L, Dollerup J, Kristiansen LC, et al. Detection of previously undiagnosed cases of COPD in a high-risk population identified in general practice. COPD. 2012;9(5):458–65.  https://doi.org/10.3109/15412555.2012.685118.CrossRefPubMedGoogle Scholar
  25. 25.
    Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–22.  https://doi.org/10.1164/ajrccm.157.5.9709032.CrossRefPubMedGoogle Scholar
  27. 27.
    Labonte LE, Tan WC, Li PZ, Mancino P, Aaron SD, Benedetti A, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194(3):285–98.  https://doi.org/10.1164/rccm.201509-1795OC.CrossRefPubMedGoogle Scholar
  28. 28.
    Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008;(2):Cd000165.  https://doi.org/10.1002/14651858.CD000165.pub3.
  29. 29.
    Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61(9):772–8.  https://doi.org/10.1136/thx.2006.060145.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Katajisto M, Koskela J, Lindqvist A, Kilpeläinen M, Laitinen T. Physical activity in COPD patients decreases short-acting bronchodilator use and the number of exacerbations. Respir Med. 109(10):1320–5.  https://doi.org/10.1016/j.rmed.2015.08.001.
  31. 31.
    Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, et al. An official American Thoracic Society/European Respiratory Society policy statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med. 2015;192(11):1373–86.  https://doi.org/10.1164/rccm.201510-1966ST.CrossRefPubMedGoogle Scholar
  32. 32.
    Criner GJ, Bourbeau J, Diekemper RL, Ouellette DR, Goodridge D, Hernandez P, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147(4):894–942.  https://doi.org/10.1378/chest.14-1676.CrossRefPubMedGoogle Scholar
  33. 33.
    Berlin I. Endocrine and metabolic effects of smoking cessation. Curr Med Res Opin. 2009;25(2):527–34.CrossRefGoogle Scholar
  34. 34.
    Ninot G. Anxiety and depression in COPD: a review. Rev Mal Respir. 2011;28(6):739–48.  https://doi.org/10.1016/j.rmr.2010.11.005.CrossRefPubMedGoogle Scholar
  35. 35.
    Zeller A. Medical therapy for smoking cessation. Ther Umschau Rev Ther. 2010;67(8):419–25.  https://doi.org/10.1024/0040-5930/a000074.CrossRefGoogle Scholar
  36. 36.
    Wilkes S. The use of bupropion SR in cigarette smoking cessation. Int J Chron Obstruct Pulmon Dis. 2008;3(1):45–53.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Ebbert JO, Wyatt KD, Hays JT, Klee EW, Hurt RD. Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence. 2010;4:355–62.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Britton J, Arnott D, McNeill A, Hopkinson N. Nicotine without smoke-putting electronic cigarettes in context. BMJ. 2016;353:i1745.  https://doi.org/10.1136/bmj.i1745.CrossRefPubMedGoogle Scholar
  39. 39.
    Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.  https://doi.org/10.1056/NEJMoa063070.CrossRefPubMedGoogle Scholar
  40. 40.
    •• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.  https://doi.org/10.1056/NEJMoa1516385. This was a seminal paper in COPD care demonstrating greater symptom and exacerbation control with a LABA/ LAMA compared to ICS/LABA in exacerbating patients with an FEV1 <60% predicted. CrossRefPubMedGoogle Scholar
  41. 41.
    Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir. 2013;22(1):92–100.  https://doi.org/10.4104/pcrj.2012.00092.CrossRefGoogle Scholar
  42. 42.
    Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–37.  https://doi.org/10.1183/09031936.00128914.CrossRefPubMedGoogle Scholar
  43. 43.
    Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.  https://doi.org/10.1056/NEJMoa1104623.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Han MK, Tayob N, Murray S, Dransfield MT, Washko G, Scanlon PD, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189(12):1503–8.  https://doi.org/10.1164/rccm.201402-0207OC.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet (London, England). 2015;385(9971):857–66.  https://doi.org/10.1016/s0140-6736(14)62410-7.CrossRefGoogle Scholar
  46. 46.
    Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, et al. A multicenter randomized controlled trial of Zephyr endobronchial valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med. 2017;196(12):1535–43.  https://doi.org/10.1164/rccm.201707-1327OC.CrossRefPubMedGoogle Scholar
  47. 47.
    Schaffer JM, Singh SK, Reitz BA, Zamanian RT, Mallidi HR. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA. 2015;313(9):936–48.  https://doi.org/10.1001/jama.2015.1175.CrossRefPubMedGoogle Scholar
  48. 48.
    Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64(8):728–35.  https://doi.org/10.1136/thx.2008.108027.CrossRefPubMedGoogle Scholar
  49. 49.
    Kauppi P, Kupiainen H, Lindqvist A, Tammilehto L, Kilpelainen M, Kinnula VL, et al. Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma. 2011;48(3):279–85.  https://doi.org/10.3109/02770903.2011.555576.CrossRefPubMedGoogle Scholar
  50. 50.
    Anzueto A, Miravitlles M. Considerations for the correct diagnosis of chronic obstructive pulmonary disease and its management with bronchodilators. Chest. 2018;  https://doi.org/10.1016/j.chest.2018.02.023.
  51. 51.
    Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18(1):73.  https://doi.org/10.1186/s12931-017-0559-0.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest. 2004;126(2):375–81.  https://doi.org/10.1378/chest.126.2.375.CrossRefPubMedGoogle Scholar
  53. 53.
    Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–71.CrossRefPubMedGoogle Scholar
  54. 54.
    Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71.  https://doi.org/10.1164/rccm.201104-0597OC.CrossRefPubMedGoogle Scholar
  55. 55.
    Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193(9):965–74.  https://doi.org/10.1164/rccm.201509-1869OC.CrossRefPubMedGoogle Scholar
  56. 56.
    Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–73.  https://doi.org/10.1016/j.chest.2016.10.003.CrossRefPubMedGoogle Scholar
  57. 57.
    Barnes NC, Sharma R, Lettis S, Calverley PMA. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374–82.  https://doi.org/10.1183/13993003.01370-2015.CrossRefPubMedGoogle Scholar
  58. 58.
    Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94.  https://doi.org/10.1056/NEJMoa1407154.CrossRefPubMedGoogle Scholar
  59. 59.
    Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–29.  https://doi.org/10.1056/NEJMoa1708208.CrossRefPubMedGoogle Scholar
  60. 60.
    Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.  https://doi.org/10.1186/1465-9921-11-122.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Roversi S, Roversi P, Spadafora G, Rossi R, Fabbri LM. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Investig. 2014;44(1):93–102.  https://doi.org/10.1111/eci.12181.CrossRefGoogle Scholar
  62. 62.
    Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–107.  https://doi.org/10.1378/chest.128.4.2099.CrossRefPubMedGoogle Scholar
  63. 63.
    Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204–12.  https://doi.org/10.1183/09031936.00114307.CrossRefPubMedGoogle Scholar
  64. 64.
    Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.  https://doi.org/10.1056/NEJMoa0909883.CrossRefPubMedGoogle Scholar
  65. 65.
    O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635–42.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary disease and sleep apnea syndrome. Am J Respir Crit Care Med. 1995;151(1):82–6.  https://doi.org/10.1164/ajrccm.151.1.7812577.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Respiratory MedicineUniversity Hospital GalwayGalwayIreland

Personalised recommendations